Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Bicycle Therapeutics plc American Depositary Shares

BCYC

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.

Last trade $3.17
Day change -$0.01 (-0.31%)
Day range $3.12 – $3.28
Volume 308,023
Market cap $223M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$222.9M
Price / earnings
—
Price / book
0.44×
Price / sales
2.67×
EV / sales
-2.96×
EV / EBITDA
1.61×

Profitability

Earnings per share
-$2.02
Return on assets
-25%
Return on equity
-28.06%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
12.09×
Quick ratio
12.09×
Cash ratio
10.57×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$177.04M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BCYC, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$34.06M$629K$887K$47.96M$11.73M$2.92M$9.98M$3.71M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$34.06M$629K$887K$47.96M$11.73M$2.92M$9.98M$3.71M
Selling, general and administrative$14.11M$14.03M$17.47M$20.89M$18.86M$18.49M$21.12M$21.59M
Research and development$33.42M$41.16M$48.9M$51.77M$58.43M$71.03M$59.06M$49.78M
Total operating expenses$47.53M$55.19M$66.37M$72.66M$77.29M$89.52M$80.18M$71.37M
Operating income-$13.48M-$54.56M-$65.48M-$24.71M-$65.55M-$86.6M-$70.2M-$67.66M
Interest expense-$45K-$44K-$48K-$57K-$44K-$54K-$51K-$52K
Income before taxes-$9.31M-$50.24M-$60.65M-$18.89M-$58.9M-$79.18M-$61.84M-$52.94M
Income taxes$1.17M$90K$172K$1.27M$205K-$231K-$1.09M-$1.08M
Net income-$10.48M-$50.33M-$60.83M-$20.15M-$59.1M-$78.95M-$60.75M-$51.85M
Net income attributable to common shareholders-$10.48M-$50.33M-$60.83M-$20.15M-$59.1M-$78.95M-$60.75M-$51.85M
EBITDA-$12.4M-$53.49M-$64.35M-$23.37M-$63.8M-$84.91M-$68.57M-$65.96M
Basic earnings per share-$0.15-$0.72-$0.87-$0.29-$0.85-$1.14-$0.88-$0.75
Diluted earnings per share-$0.15-$0.72-$0.87-$0.29-$0.85-$1.14-$0.88-$0.75

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - Drug Sales, Patent, Price, Dosage, Proprietary Technologies & Outlook

The global Peptide Drug Conjugate (PDC) market is projected to reach $1.5 billion by 2031, growing at over 14% CAGR from 2021-2025. PDCs offer targeted drug delivery solutions for oncology and other diseases with reduced systemic toxicity. The market features over 50 clinical candidates and 18 proprietary technologies, with major players including Novartis, Oncopeptides, Bicycle Therapeutics, Cybrexa Therapeutics, and PepGen driving innovation through strategic partnerships and technological advancements in peptide design and linker technologies.

GlobeNewswire Inc.

Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight

The advanced urothelial carcinoma market is witnessing significant growth, driven by an aging population and the rising prevalence of metastatic cases. Advances in immunotherapy and targeted treatments are transforming the treatment landscape, with over 20 key companies developing new therapies.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.